

CONCORD BIOTECH LIMITED

B-1601-1602, B-wing Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380015, Gujarat.

Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440

Email ID: complianceofficer@concordbiotech.com

May 02, 2025

To The Manager, Listing Department National Stock Exchange of India Ltd. Plot No. C/1 G Block, Bandra-Kurla Complex, Bandra (East), Mumbai -400 051 Symbol: CONCORDBIO	To General Manager, Listing Department BSE Limited Phiroze Jeejabhoy Towers, Dalal Street, Mumbai - 400 001 Scrip Code: 543960
--	--

Subject: Intimation about completion of inspection by United States Food and Drug Administration (USFDA) of our API facility at Dholka.

Ref.: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company has announced the completion of the inspection of its API facility at Dholka. The inspection took place from April 28 to May 2, 2025.

At the conclusion of the inspection, the USFDA issued Form 483 with four observations. According to the Company, these observations are procedural in nature and none of them are related to data integrity.

The Company states that it will provide a detailed response to the USFDA within the required timeframe and is confident of addressing the observations expeditiously.

Kindly take the above information on record

Thanking You

For Concord Biotech Limited

Prakash Sajnani
Company Secretary and Compliance Officer
M. No. F6242